Patents Examined by D. L. Jones
  • Residualizing linkers and uses thereof
    Patent number: 10758636
    Abstract: The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: September 1, 2020
    Assignee: CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
    Inventors: John Fitzmaurice Valliant, Eric Steven Burak, Neil Grant Cockburn, Alla Darwish, Joel Adamson Drewry, John Richard Forbes, Meiduo Hu, Ryan Wayne Simms, Karin Ann Stephenson, Tao Wu
  • Solid cyanine dyes
    Patent number: 10758631
    Abstract: Polymorphs of Formula I, which is 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate and methods of making are provided. A method for organ imaging, comprising administering to a subject, a diagnostic effective amount of a composition comprising a polymorph of Formula I are also provided. In one embodiment, the organ includes one or more of kidney, bladder, ureter, urethra, bile ducts, liver, and gall bladder.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: September 1, 2020
    Assignee: LI-COR, INC.
    Inventors: Vassil Elitzin, William M. Volcheck, Katie Schaepe, Rahul Patil
  • Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
    Patent number: 10745365
    Abstract: A method to detect the presence or amount of at least one molecule in a sample which employs a derivative of luciferin or a derivative of a fluorophore is provided. Compounds and compositions for carrying out the methods of the invention are also provided.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: August 18, 2020
    Assignee: Promega Corporation
    Inventors: James J. Cali, William Daily, Erika Hawkins, Dieter Klaubert, Jianquan Liu, Poncho Meisenheimer, Michael Scurria, John W. Shultz, James Unch, Michael P. Valley, Keith V. Wood, Wenhui Zhou
  • Trifunctional and completely clearable specific targeting agents and methods thereof
    Patent number: 10744211
    Abstract: The invention provides a novel trifunctional targeting construct and related compositions and methods that are useful in therapeutic, diagnostic (including imaging) of various biological and/or pathological conditions and diseases such as cancers and diabetes. The trifunctional targeting construct of the invention provides enhanced clearing step and reduced non-specific background via complete clearance of undesired antibody conjugates.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: August 18, 2020
    Assignee: University of Massachusetts
    Inventors: Guozheng Liu, Shuping Dou
  • Glucose analogs for diagnosis states
    Patent number: 10736973
    Abstract: Provided are methods and formulations for imaging at least one body region of a subject, employing a glucose analog resistant or inactive to phosphrylation, or which is not a substrate for hexokinase.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: August 11, 2020
    Assignee: TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP
    Inventors: Gil Navon, Michal Rivlin, Ilan Tsarfaty
  • Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
    Patent number: 10736976
    Abstract: Radiolabeled anti-PD-L1 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of PD-L1 proteins in a patient or sample.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: August 11, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Marcus Kelly, Dangshe Ma, William Olson, Gavin Thurston
  • Animal models for evaluating pharmaceutical compounds
    Patent number: 10729791
    Abstract: The application relates to methods for determining a parameter such as toxicity and pharmacokinetic behavior for a pharmaceutical compound against a disease or disorder. The test animals being used are non-human animals not suffering from or is not showing symptoms or signs of the disorder and which do not provoke an immune response against said pharmaceutical compound. These animals are obtainable by administration of a peptide comprising an oxidoreductase motif further comprising an NKT peptide epitope or an MHC class II T cell epitope of said pharmaceutical compound, wherein said motif and said epitope are separated by a linker of between 0 and 4 amino acids.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: August 4, 2020
    Assignee: IMCYSE SA
    Inventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
  • Method for imaging arthritis
    Patent number: 10729793
    Abstract: The invention relates to a method of imaging arthritis in a subject, comprising administering to the subject a tracer which comprises a peptide conjugated to a radionuclide, and imaging the subject by 2D nuclear imaging or by 3D detection of single-photon emission events.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: August 4, 2020
    Assignee: GUY'S AND ST. THOMAS' HOSPITAL NHS FOUNDATION TRUST
    Inventor: Toby Garrood
  • Compositions and methods for detecting protein sulfenylation
    Patent number: 10718778
    Abstract: The present invention relates to methods for detecting sulfenylation within thiol groups in proteins, metabolites, or materials. Protein sulfenylation (Cys-SOH) describes the reversible post-translational modification of protein thiols by hydrogen peroxide, and plays a central role in oxidative signaling (see, e.g., Paulsen, C. E. & Carroll, K. S. 2013 Chemical Reviews 113, 4633-679). Growth factor stimulation activates NADPH oxidase enzymes, releasing a local burst of hydrogen peroxide, which transiently oxidizes the nuclcophilic cysteine of protein phosphatases and other proximal redox active thiols (see, e.g., Paulsen, C. E. et al., 2012 Nature Chemical Biology 8, 57-64). In addition to masking functional cysteine's, sulfenylation is also a critical intermediate towards irreversible cysteine oxidation.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: July 21, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Brent R. Martin, Christopher Baker Tom
  • Cryptate compounds
    Patent number: 10717741
    Abstract: Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: July 21, 2020
    Assignees: Australian Nuclear Science and Technology Organisation, The Australian National University
    Inventors: Suzanne Virginia Smith, Eskender Mume, Gary James Perkins
  • Cleavable lipids
    Patent number: 10702478
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g. as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: July 7, 2020
    Assignee: Translate Bio, Inc.
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang
  • Method for treating and prognosing cancer
    Patent number: 10697965
    Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: June 30, 2020
    Assignees: INSERM (INSITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, UNIVERSITE D'ANGERS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre-Francois Cartron, Mathilde Cheray, Francois Valette
  • Alpha-emitting complexes
    Patent number: 10682430
    Abstract: The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: June 16, 2020
    Assignee: BAYER AS
    Inventor: Thomas Ramdahl
  • Method for preparing cell targeting conjugates, and the complexes obtained
    Patent number: 10668162
    Abstract: A first aspect of the disclosure relates to a method for preparing cell-targeting conjugates by coupling at least one functional moiety, such as a therapeutic compound, diagnostic compound or chelating agent to a targeting moiety. A second aspect of this disclosure relates to the cell-targeting conjugates obtainable with this method. A third aspect of the disclosure described herein relates to pharmaceutical compositions comprising the cell-targeting conjugates.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: June 2, 2020
    Assignee: LinXis B.V.
    Inventors: Hendrik Jan Houthoff, Augustinus A. M. S. Van Dongen, Robbert Jan Kok, Dennis Christian Johannes Waalboer, Sytze Jan Buwalda, Niels Jurriaan Sijbrandi
  • Cathepsin-binding compounds bound to a carrier and their diagnostic use
    Patent number: 10668175
    Abstract: The invention relates to Cathepsin-binding compounds bound to a carrier comprising a diagnostic moiety, for use in the diagnosis of inflammatory diseases, and/or for use in the diagnosis of neoplastic diseases, wherein the Cathepsin-binding compound binds to inflammatory cells of the tumour stroma. The invention also relates to Cathepsin B-targeting compounds and Cathepsin B-binding and liposome-binding compounds.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 2, 2020
    Assignee: J. Stefan Institute
    Inventors: Olga Vasiljeva, Georgy Mikhaylov, Boris Turk, Norbert Schaschke
  • Thrombus imaging aptamers and methods of using same
    Patent number: 10660973
    Abstract: Provided herein are imaging agents, antidotes to the imaging agents and methods of using the same to image a thrombus or blood clot or thrombin including sites of thrombin accumulation and to diagnose and treat thrombosis. The imaging agents include an aptamer capable of binding the thrombus or thrombin in particular linked to a reporter moiety. The imaging agents may be used to label the thrombus or sites of thrombin accumulation. Antidotes capable of binding to the aptamer in the imaging agent are also provided. The antidotes may further be linked to a quencher capable of quenching the reporter moiety.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: May 26, 2020
    Assignee: Duke University
    Inventors: Bruce A. Sullenger, Kady-Ann C. Steen-Burrell, Bethany Powell Gray
  • Imaging agents for imaging protease activity and uses thereof
    Patent number: 10646591
    Abstract: Disclosed are imaging agents having the following Formula I: wherein F is a near infrared fluorophore, S is an enzymatically cleavable oligopeptide, Q is a fluorescence quencher molecule, and M is a moiety selected from the group consisting of PEG or derivative thereof and a targeting ligand, and wherein F, Q and M are linked to separate amino acids of the enzymatically cleavable oligopeptide. Compositions comprising such compounds, as well as methods of use, methods of identifying a cell or a population of cells in vivo expressing a protease of interest, and methods of treating a disease through imaging are also disclosed.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: May 12, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Xiaoyuan Chen, Seulki Lee, Lei Zhu
  • Oligosaccharide conjugates for targeting bacteria and uses related thereto
    Patent number: 10646580
    Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 12, 2020
    Assignees: Emory University, Georgia Tech Research Corporation, Georgia State University Research Foundation, Inc.
    Inventors: Niren Murthy, Eric Seth Gilbert, Xinghai Ning, Mark Goodman, Bryan Stubblefield
  • HER2 polypeptides useful for imaging and monitoring tumors and cancers
    Patent number: 10646600
    Abstract: A method of use of an isolated polypeptide conjugated with a radionuclide, wherein the isolated polypeptide binds specifically to HER2, or a variant thereof is described. The method is for monitoring the response to HSP90 inhibition and comprises the use of the isolated polypeptide conjugated with 18F. The application also describes the use of an isolated polypeptide conjugated with 18F, wherein the isolated polypeptide binds specifically to HER2 or variants thereof, as an imaging agent to monitor uptake thereof to measure HSP90 inhibition.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: May 12, 2020
    Assignees: IMPERIAL INNOVATIONS LIMITED, GE HEALTHCARE LIMITED
    Inventors: Duncan Robert R. Hiscock, Eric Aboagye, Peter Iveson, Quang-De Nguyen, Susan Hoppmann, Sebastian Trousil, Maciej Kaliszczak, Giampaolo Tomasi
  • Cage-like bifunctional chelators, copper-64 radiopharmaceuticals and PET imaging using the same
    Patent number: 10646598
    Abstract: Disclosed is a class of versatile Sarcophagine based bifunctional chelators (BFCs) containing a hexa-aza cage for labeling with metals having either imaging, therapeutic or contrast applications radiolabeling and one or more linkers (A) and (B). The compounds have the general formula where A is a functional group selected from group consisting of an amine, a carboxylic acid, an ester, a carbonyl, a thiol, an azide and an alkene, and B is a functional group selected from the group consisting of hydrogen, an amine, a carboxylic acid, and ester, a carbonyl, a thiol, an azide and an alkene. Also disclosed are conjugate of the BFC and a targeting moiety, which may be a peptide or antibody. Also disclosed are metal complexes of the BFC/targeting moiety conjugates that are useful as radiopharmaceuticals, imaging agents or contrast agents.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: May 12, 2020
    Assignee: University of Southern California
    Inventors: Peter S. Conti, Hancheng Cai, Zibo Li, Shuanglong Liu